Antinauseants Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Antinauseants Market is Segmented By Drug Type (Serotonin-Receptor Antagonists, Anticholinergics, Glucocorticoids, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Others), By Application (Chemotherapy, Gastroenteritis, Post-Operative Surgery, Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Antinauseants Market Size

Global Antinauseants Market reached US$ 2.3 billion in 2023 and is expected to reach US$ 3.7 billion by 2031 growing with a CAGR of 6.2% during the forecast period 2024-2031.

Antinauseants, also known as antiemetics, help prevent or alleviate nausea and vomiting. These two symptoms are prevalent and can be caused by many different conditions, therapies, procedures, and medications. Though vomiting is considered to be a protective reflex of the body to expel toxic substances in the stomach and gut, antiemetic drugs are often necessary to suppress vomiting, especially if there’s severe dehydration.

These drugs are often used to treat conditions such as motion sickness, chemotherapy-induced nausea and vomiting, and postoperative nausea and vomiting. The market is driven by factors such as the rising prevalence of cancer and gastroenteritis and the surge in research and development activities.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Rising prevalence of cancer and gastroenteritis

The demand for the global antinauseant drugs market is driven by multiple factors. One of the primary factors driving the market is the rising incidence of cancer and the increase in chemotherapy treatments are major drivers of the antinauseant drugs market. Chemotherapy-induced nausea and vomiting (CINV) is a common side effect that requires the use of antiemetic medications to manage.

According to the NIH publication in July 2023, about 70% to 80% of adults with cancer experience chemotherapy‐induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.

Similarly, the high prevalence of gastroenteritis globally is also contributing to the demand for antiemetic drugs. Gastroenteritis treatments have witnessed several adverse effects of nausea and vomiting. Antiemetic drugs are useful for controlling such side effects during treatments. 

Moreover, key players' awareness programs and drug approvals would propel this market growth in this region. For instance, in October 2023, Astellas Pharma Inc. presented research results at the European Society for Medical Oncology (ESMO) Congress 2023. During this presentation, the company also presented an abstract focusing on the effects of antiemetics on gastric injury and emesis frequency in ferrets.

Also, in April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. Food and Drug Administration (FDA) for Gimoti (metoclopramide) nasal spray. Evoke now has exclusive marketing privileges over three years from the initial date of approval under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist that is used as a potent antiemetic drug.

Restraints

Factors such as the adverse effects associated with the drugs, lack of awareness among individuals, limited treatment availability, and stringent regulatory requirements, are expected to hamper the market.

Market Segment Analysis

The global antinauseant drugs market is segmented based on drug type, application, distribution channels, and region.

The serotonin-receptor antagonists segment accounted for approximately 45.3% of the global antinauseant drugs market share

The serotonin-receptor antagonists segment is expected to hold the largest market share over the forecast period. 5HT3 antagonists are routinely used as antiemetics postoperatively and during chemotherapy. These include numerous launched products – azasetron, granisetron, indisetron, ondansetron, palonosetron, dolasetron, ramosetron, and tropisetron.

Moreover, key players in the industry drug launches & approvals, and awareness programs would drive this segment growth. For instance, in July 2024, Amneal Pharmaceuticals, Inc. announced the launch of FOCINVEZ, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 does not require reconstitution or dilution, and can be administered directly from the vial using the included vial hanger.

Focinvez and Cinvanti are recommended for use in the treatment of acute and delayed nausea and vomiting, in combination with serotonin (5-HT3) receptor antagonists and a corticosteroid (usually dexamethasone). FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents.

According to the article published by the Canadian Institutes of Health Research in May 2022, Ondansetron, a 5-HT3 antagonist approved in Canada as an antiemetic. This drug is used for nausea and vomiting associated with chemotherapy and post-operation.

Market Geographical Share

North America accounted for approximately 42.2% of the global antinauseant drugs market share. 

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of cancer & chemotherapy-induced nausea and vomiting (CINV) and gastroenteritis in the U.S., which would propel this market growth in this region.

According to the American Cancer Society, in December 2023, around 609,820 cancer deaths and 1,958,310 new cancer cases are estimated to occur in the U.S. Thus, the prevalence of such diseases causing vomiting and nausea is anticipated to propel the market growth over the forecast period. 

Moreover, key players in the industry strategies such as mergers & acquisitions and drug approvals would propel this market growth in this region. For instance, in January 2022, Cumberland Pharmaceuticals Inc. announced that it had entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. SANCUSO is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. 

Also, in September 2022, Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.

Market Segmentation

By Drug Type

• Serotonin-Receptor Antagonists
• Anticholinergics
• Glucocorticoids
• Dopamine Receptor Antagonists
• Neurokinin Receptor Antagonists
• Others 

By Application

• Chemotherapy
• Gastroenteritis
• Post-Operative Surgery
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • The rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Major Players

The major global players in the antinauseants market include Heron Therapeutics, Inc., TAIHO PHARMACEUTICAL CO., LTD, Pfizer Inc., Merck & Co., Inc., GLENMARK PHARMACEUTICALS LTD, Amneal Pharmaceuticals LLC, Akums Drugs and Pharmaceuticals Ltd, Astellas Pharma Inc, EVOKE PHARMA, and Barhemsys.

Key Developments

• In December 2023, Akums Drugs and Pharmaceuticals announced the launch of Doxylamine + Pyridoxine extended-release tablets, a therapy approved by the CSDCO, India and the USFDA. This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy.
• In January 2023, Glenmark Pharmaceuticals Ltd. launched in India a unique I.V. injection formulation, AKYNZEO I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company. AKYNZEO I.V. is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg).
• In May 2022, Taiho Pharmaceutical Co., Ltd. announced that Arokaris I.V. infusion 235mg (generic name: fosnetupitant chloride hydrochloride), a selective NK1 receptor antagonist antiemetic drug, has been listed on the National Health Insurance (NHI) reimbursement price list.

Why Purchase the Report?

• To visualize the global antinauseant drugs market segmentation based on drug type, application, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of the antinauseant drugs market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global antinauseants drug market report would provide approximately 62 tables, 57 figures, and 182 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies